Joby Aviation closes $591 million stock offering with full underwriter option
Lilly Endowment Inc. sold 26,795 shares of Eli Lilly & Co (NYSE:LLY) on October 7, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $848.009, with prices ranging from $848.00 to $848.32.
The total value of the shares sold by Lilly Endowment Inc. amounted to $22,722,401. Following the transaction, Lilly Endowment Inc. still owns 94,649,000 shares of Eli Lilly & Co.
Peter A. Buck, Vice President for Investments and Grants Administration, signed the report on behalf of Lilly Endowment Inc.
In other recent news, Eli Lilly’s upcoming third-quarter earnings report has attracted attention, with Guggenheim raising its price target for the company to $948, highlighting the strength of its diabetes drug, tirzepatide. The firm forecasts third-quarter sales of Mounjaro at $5.49 billion, slightly above the consensus estimate. Meanwhile, Eli Lilly announced that its ulcerative colitis treatment, Omvoh, demonstrated sustained efficacy over four years, with 80% of patients maintaining clinical remission and 93% experiencing significant improvement in bowel urgency. TD Cowen has reiterated its Buy rating on Eli Lilly, maintaining a price target of $960, citing the company’s strong growth prospects and consistent innovation. Guggenheim also reiterated its Buy rating, maintaining a price target of $875, and noted the company’s expected sustainable gross margins and strong growth outlook for 2025. These developments provide a comprehensive view of Eli Lilly’s current market position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.